Life expectancy of women with lupus nephritis now approaches that of the general population

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1135-1141

  Stratta, P ^a   Mesiano, P ^b   Campo, A ^c   Grill, A ^d   Ferrero, S ^d   Santi, S ^e   Besso, L ^f   Mazzucco, G ^g   Rosso, S ^h   Spitale, A ^h   Fop, F ^f   Ciccone, G ^h  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Department of Clinical and Experimental Medicine   (Italy)

^c Alba Hospital   (Italy)

^d Rivoli Hospital   (Italy)

^e Chivasso Hospital   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g Sections Pathology   (Italy)

^h CPO Piemonte Cancer Registry   (Italy)

Author keywords

Female sex; Immunosuppressant; Lupus nephritis; Relative survival; Renal diseases; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

EID: 76349097789     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200432     Document Type: Article

References (24)

1. Donadio JV, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993; 21:239-250.
2. Schwartz MM, Korbet SM, Lewis EJ; Collaborative Study Group. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008; 23:1298-306.
3. Wardle EN. Lupus nephritis in the new millennium. Nephrol Dial Transplant 2002; 17:519.
4. Ponticelli C, Zucchelli P, Moroni G, Cagnoli L, Banfi G, Fascuali S. Long term prognosis of diffuse lupus nephritis. Clin Nephrol 1987; 28:263-71.
5. Austin HA, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH, Decker J. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614-9.
6. Klippe JH. Is aggressive therapy effective for lupus? Rheumatic Dis Cin North Am 1993; 19:249-63.
7. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35:904-14.
8. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis N Engl J Med 2004; 350:971-80.
9. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50:3934-40.
10. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14:890-5.
11. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563-9.
12. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119:355.e25-33.
13. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22:2531-9.
14. Chrysochou C, Randhawa H, Reeve R, Waldek S, Wood GN, O'Donoghue DJ, Kalra PA. Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study. QJM 2008; 101:313-6.
15. Grootscholten C, Bajema IM, Florquin S, et al. Dutch Working Party on Systemic Lupus Erythematosus. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56:924-37.
16. Stratta P, Canavese C, Santi S, Ciccone G, Rosso S. Systemic lupus erythematosus. Lancet 2001; 358: 586-7.
17. Stratta P, Marcuccio C, Campo A, et al. Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int J Immunopathol Pharmacol 2008; 21:631-42.
18. Churg J, Sobin LH. Lupus Nephritis. In: Renal disease, classification and atlas of glomerular diseases. Edited Tokyo; New York , Igaku - Shoin, 1982:127-149.
19. Weening JJ, D'Agati VD, Schwartz MM, et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol 2004; 15:241-50.
20. Austin HA, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75:382-91.
21. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25:689-95.
22. Hakulinen T, Tenkanen L, Abeywickrama K, Paivarinta L. Testing equality of relative survival patterns based on aggregated data. Biometrics 1987; 43:313-25.
23. Stratta P, Canavese C, Lupo A, Pozzi C, Passerini P, Cagnoli L, Manno C, Strippoli GF. [Treating lupus nephritis: guideline from the Italian Society of Nephrology]. G Ital Nefrol 2007; 24(S)37:50-63. Italian.
24. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009; 24:15-20.